Editorial
The Federal ‘Right To Try’ Act: An Answer to New Treatments During Terminal Illness?
Pamela Hallquist Viale, RN, MS, CNS, ANP
J Adv Pract Oncol 2017;8:334–336 |
https://doi.org/10.6004/jadpro.2017.8.4.2 |
© 2017 Harborside Press®
ABSTRACT
The newly proposed Federal “Right to Try” Act permits terminally ill patients to try experimental therapies that have completed phase I testing but have not been approved by the FDA. However, there are concerning provisions of the legislature regarding liability and costs.
For access to the full length article, please
sign in.
